Mrna-1273
Deferred VaccinesNot applicable line
Prevention of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in adults aged 75 years or more (2 doses per year), adults aged 65-74 years (1 dose per year), adults aged 18-64 years with severe immunocompromise (1 dose per year), and Aboriginal and Torres Strait Islander adults aged 50 to 74 years (1 dose per year).
1
Submissions
2026–26
On the record
—
ICER range
—
Cost basis
Cost-effectiveness
No ICER stated in the public text. The submission included a cost-utility analysis, but no numeric ICER is printed in this PSD extract.
Decision context
PopulationAdults aged 18 years and older in accordance with ATAGI-recommended populations: aged 75+ (every 6 months), aged 65-74 (every 12 months), aged 18-64 with severe immunocompromise (every 12 months), and Aboriginal and Torres Strait Islander aged 50-74 (every 12 months).
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2026 | Deferred | no vaccination | — | RCT |
Similar precedents
Mrna-134571%Pcv1566%Raxtozinameran65%Pneumococcal Conjugate Vaccine 13-Valent (13vpcv) And Pneumococcal Polysaccharide Vaccine 23-Valent (23vppv)65%Varicella Zoster Virus Recombinant Vaccine64%Pneumococcal Conjugate Vaccine, 13-Valent64%Zoster Virus Vaccine Live64%Zoster Virus Vaccine Live (Oka/Merk)63%